Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Volker Wacheck_2024
VIEWPOINTS

Volker Wacheck Discusses the Approval of the Lonsurf Combination Drug for the Treatment of Colorectal Cancer

Shots:  Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer  While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
January 2, 2024

Read more

VIEWPOINTS_Amy Taneja_2023
VIEWPOINTS

Women Health: Amy Taneja in a Striking Conversation with PharmaShots Shares the Highlights of Jada System

Shots:  Amy Taneja, in a stimulating conversation with PharmaShots, shares the highlights of the Jada system, a vacuum-induced hemorrhage control device   Amy describes how the Jada system differs from traditional methods of controlling PPH while explaining how the system works   JADA, which is now being shipped to Chile, Hong Kong, Puerto Rico, New Zealand, and…
December 26, 2023

Read more

VIEWPOINTS_Justin Schreiber_2023
VIEWPOINTS

Justin Schreiber Discusses the Recently Launched D2C Telehealth Model for Hormone Therapy

Shots:   Justin Schreiber, Chairman, and CEO of, LifeMD, in an illuminating conversation with PharmaShots, discusses the recent partnership with ASCEND Therapeutics    LifeMD, a virtual primary care company, and ASCEND Therapeutics, a leading women's health pharmaceutical company, came together to bring an integrated direct-to-consumer telehealth model to enhance the way women receive care for their menopause…
December 21, 2023

Read more

VIEWPOINTS_Dr. Lotus Mallbris_2023
VIEWPOINTS

Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults

Shots:    Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease    While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…
December 19, 2023

Read more

VIEWPOINTS_Helen Yeh1_Naim Shehadeh2_2023
VIEWPOINTS

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots: At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…
December 11, 2023

Read more

EVENTS

Webinar Recap: Successful Drug Discovery-Collaboration Among Multiple Functions

Illuminating, informative, and engaging, our recent webinar on Successful Drug Discovery-Collaboration Among Multiple Functions with Eurofins Advinus, was an energy-packed session that highlighted the intricacies of the drug discovery process. The webinar delved deep into the nuances that are necessary for a successful drug discovery. The session was filled with stimulating case studies, highlighting crucial aspects like…
December 8, 2023

Read more

VIEWPOINTS_Kylen Cieslak1_Robert Ley2_2023
VIEWPOINTS

Kylen Cieslak and Robert Ley Discuss the Expansion of Thermo Fisher Scientific’s Services Central in the US & EU

Shots:  Kylen Cieslak, Senior Manager, Service Marketing, Thermo Fisher Scientific, and Robert Ley, Senior Strategic Product Manager, Thermo Fisher Scientific in a stirring conversation with PharmaShots   Kylen and Robert highlighted the recent expansion of Thermo Fisher Scientific’s Services Central in the United States and Europe   Services Central is an online platform intended to provide 24/7…
December 7, 2023

Read more

VIEWPOINTS_Mohamed Eid_2023
VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots:  Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease   Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…
December 5, 2023

Read more

Load more